LatchBio logo

LatchBio

Provides biocomputational infrastructure to accelerate laboratory data analysis workflows.

ShareLink copied

The record

Vertical
Biotech & Pharma
Sub-segment
Bioinformatics platform
Product type
Platform software
Stage
Series A
Headquarters
San Francisco, United States
Region
North America
Founded
2021
Total funding
$33M

What they do

Latch lets biologists run bioinformatics tools and pipelines on large experimental datasets without writing code. Its cloud software supports uploading, organising and analysing genomic sequencing data for biotechnology companies and academic laboratories, and is free for academics. The company raised a $28 million Series A in June 2022, co-led by Coatue and Lux Capital.

Leadership & founders

Leadership as of 14 November 2026.

Investors

History and progression

How LatchBio got here, step by step.

  1. 2 June 2022

    $28 million Series A

    Co-led by Coatue and Lux Capital with Hummingbird Ventures, Caffeinated Capital, Haystack and Fifty Years.

Key products

Latch platform
Code-free cloud platform for biologists to run bioinformatics tools and pipelines on large experimental datasets; free for academics

Recent news

  1. 2 June 2022

    TechCrunch: LatchBio raises $28M

Related companies

Your daily HealthTech Signal

No hype. Just signal.

Get the latest HealthTech news, understand why it matters, and see where the industry is headed.

5-minute read Delivered daily Unsubscribe anytime

Read by teams at companies like:

Mayo Clinic logoMayo ClinicCleveland Clinic logoCleveland ClinicJohns Hopkins logoJohns HopkinsKaiser Permanente logoKaiser PermanenteEpic logoEpicPhilips logoPhilipsMedtronic logoMedtronicGE HealthCare logoGE HealthCare

Is this your company? Get a Verified profile